MoonLake Immunotherapeutics's total assets for Q4 2024 were $477.93B, an increase of 92127.13% from the previous quarter. MLTX total liabilities were $24.54B for the fiscal quarter, a 107959.53% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.